Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Context Therapeutics (NASDAQ: CNTX) Drifts Lower: Is the Pullback Creating a New Setup?

Few small-cap oncology names carry as wide a gap between clinical ambition andMarket Valueas Context Therapeutics Inc. (NASDAQ: CNTX). The immuno-oncology developer trades near the $0.37 level with a market capitalization around $34 million, even as its pipeline of T-cell engaging bispecific antibodies advances …

Nitika (Guest) | 10 September 2026

Cosmos Health (NASDAQ:COSM) Stock Retreats: What Could Turn It Around?

● Cosmos Health has been trying to reframe its story from a volatile small-cap into a growing, internationally diversified healthcare and wellness business.

Nitish Kishor | 10 September 2026

Coya Therapeutics (NASDAQ:COYA) Shares Hold Steady: What Could Break the Deadlock?

● Coya develops therapies designed to enhance the function of regulatory T cells (Tregs), immune cells that help control the inflammation implicated in diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Nitish Kishor | 10 September 2026

Caribou Biosciences (NASDAQ:CRBU) Shares Drop: Why CRBU Is Under Pressure

● Caribou Biosciences has become a case study in the gap between promising science and a punishing market for early-stage biotech.

Nitish Kishor | 10 September 2026

Curis (NASDAQ:CRIS) Stock: What Could Turn the Precision-Oncology Developer Around

Curis, Inc (NASDAQ:CRIS) has slipped again, and the pullback lands on a stock that has already endured a brutal multi-year decline. The Lexington, Massachusetts cancer-drug developer trades deep in micro-cap territory after repeated financings, yet its lead program keeps generating clinical headlines that draw …

Nitish Kishor | 10 September 2026

Champions Oncology, Inc (NASDAQ:CSBR) Stock Eases Back: Key Levels and Catalysts to Watch

● For a small-cap services company, trading tends to follow reported financial performance and sentiment toward the biotech funding cycle, since Champions' customers are the very drug developers whose research budgets rise and fall withCapitalavailability.

Nitish Kishor | 10 September 2026

CuraScientific (OTC:CSTF) Sells Real Cannabis Products, But Its Filings Have Gone Silent

CuraScientific Corp (OTC:CSTF) sits at the intersection of two of the market's riskiest corners: sub-penny over-the-counter stocks and the cannabis consumer-products business. Trading at a fraction of a cent with aMarket Valuein the low thousands of dollars in the last closing session, the company …

Nitish Kishor | 10 September 2026

CERo Therapeutics (OTC:CERO) Stock: Is This a Point Worth Examining

Trading at barely more than a penny and carrying aMarket Valuein the hundreds of thousands of dollars, CERo Therapeutics Holdings, Inc. (OTC:CERO) sits among the most speculative names in cell therapy. The company has been trading over the counter after moving off the Nasdaq, …

Nitish Kishor | 10 September 2026

ContraFect (OTC:CFRXQ) Stock: The Anatomy of a Biotech Wind-Down Investors Should Understand

The ticker CFRXQ tells much of the story before a single financial statement is opened. The trailing 'Q' is the market's shorthand for a company in bankruptcy, and ContraFect Corporation (OTC:CFRXQ) earned it the hard way.

Nitish Kishor | 10 September 2026

Cognition Therapeutics (NASDAQ:CGTX) Stock: A Minor Dip Against a Clearer Regulatory Roadmap

Clinical-stage neurology names tend to trade on regulatory signposts rather than day-to-day price action, and Cognition Therapeutics fits that mold. The Nasdaq-listed company has spent 2026 sharpening the regulatory path for its lead drug candidate, even as its shares hover near the psychologically important …

Nitish Kishor | 10 September 2026
Support

Hi! How can we help you today?

Loading…